Tempest Therapeutics, Inc. (TPST): Entry into a Material Definitive Agreement
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 11, 2026, Tempest Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Investor ”), pur
How this was made
The 30-second read
Why it matters
The $2.5 M raise provides working capital but introduces warrant‑related dilution; price reaction likely muted.
Market read
A micro‑cap biotech financing event with limited market impact.
What to watch
Potential future upside if warrants are exercised and trigger additional capital.
Background
Tempest Therapeutics is a clinical‑stage biotech company filing a material definitive agreement for a private placement.
Ticker impact
Tempest Therapeutics filed an 8‑K announcing a private placement of pre‑funded and common warrants raising about $2.5 million.
Potential slight upside as cash improves liquidity, but dilution may cap gains.
The raise is small relative to market cap, but the issuance of warrants could modestly affect share supply.
Market effects
Minor impact on biotech financing trends; no broader sector shift.
Limited to US micro‑cap market.
None
Counterpoint
The small raise may be a signal of cash constraints, suggesting caution.
Key entities
- companyTempest Therapeutics, Inc.
Biotech issuer of the securities.
- placement_agentH.C. Wainwright & Co., LLC
Exclusive placement agent for the private placement.
